ALX Oncology Holdings Inc. ALXO

1.31 (0.05) (3.68%) as of 25 Sep

Follow ALXO

Insider Buys (last 12m)

Insider Buys alert about insiders buying in the last 12 month

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio	—	—	—	—	+8 more quarters Free account
EV/Sales	—	—	—	—
EV/FCF	—	—	—	—
Quick Ratio	9.36	6.95	1.82	2.19
Current Ratio	9.71	7.21	2.07	2.40
Net Debt/EBITDA	7.05	6.96	1.52	2.24
Debt/Assets	6.03%	4.77%	16.51%	12.22%
Debt/Equity	0.07	0.06	0.38	0.23
Asset Turnover	0.00	0.00	0.00	0.00
Operating CF/Net income	0.89	1.04	0.83	0.77
Capex/Depreciation	(0.14)	(2.63)	(1.32)	(9.33)
Interest Coverage	0.00	0.00	0.00	0.00
Research and Development Expense of Revenue	0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue	0.00%	0.00%	0.00%	0.00%
Intangible Assets out of Total Assets	0.00	0.00	0.00	0.00
Share Based Compensation of Revenue	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Yield	—	—	—	—
Revenue per Share	0.00	0.00	0.00	0.00
Operating CF per Share	(0.12)	(0.18)	(0.35)	(0.32)
Capex per Share	0.00	0.00	0.00	0.00
Free Cash Flow per Share	(0.12)	(0.18)	(0.35)	(0.32)
Cash per Share	1.02	1.34	0.83	1.13
Shareholders Equity per Share	1.00	1.45	0.48	0.84
Interest Debt per Share	0.00	0.00	0.00	0.00
Book value per Share	1.00	1.45	0.48	0.84
Free Cash Flow	(16.03)	(18.70)	(19.03)	(17.15)
Working Capital	128.68	125.39	26.17	38.79
Capital Expenditures	0.03	(0.05)	(0.05)	(0.06)
Net Current Asset Value	118.82	118.58	17.66	28.59
EV/EBIT	—	—	—	—
Capex to Sales	0.00	0.00	0.00	0.00
Net Profit Margin	0.00%	0.00%	0.00%	0.00%
Other line items
Average Payables	3.96	3.90	4.71	7.24
Average Assets	128.07	149.61	103.41	134.22
Average Common Equity	100.30	119.82	69.80	90.80

Columns are period end dates

Powerpack